0001209191-21-043377.txt : 20210625
0001209191-21-043377.hdr.sgml : 20210625
20210625180830
ACCESSION NUMBER: 0001209191-21-043377
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20210623
FILED AS OF DATE: 20210625
DATE AS OF CHANGE: 20210625
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: GOODMAN JESSE
CENTRAL INDEX KEY: 0001756929
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37766
FILM NUMBER: 211049410
MAIL ADDRESS:
STREET 1: C/O INTELLIA THERAPEUTICS, INC.
STREET 2: 40 ERIE STREET, SUITE 130
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Intellia Therapeutics, Inc.
CENTRAL INDEX KEY: 0001652130
STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835]
IRS NUMBER: 364785571
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 40 ERIE STREET
STREET 2: SUITE 130
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
BUSINESS PHONE: 857-285-6200
MAIL ADDRESS:
STREET 1: 40 ERIE STREET
STREET 2: SUITE 130
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2021-06-23
0
0001652130
Intellia Therapeutics, Inc.
NTLA
0001756929
GOODMAN JESSE
C/O INTELLIA THERAPEUTICS, INC.
40 ERIE STREET; SUITE 130
CAMBRIDGE
MA
02139
1
0
0
0
Common Stock
2021-06-23
4
A
0
2094
0.00
A
2094
D
Stock Option (right to buy)
83.59
2021-06-23
4
A
0
3382
0.00
A
2031-06-22
Common Stock
3382
3382
D
Stock Option (right to buy)
18.52
2028-10-28
Common Stock
38000
38000
D
Based on a grant of restricted stock units representing a contingent right to receive one share of Intellia common stock for each restricted stock unit.
This option was granted on June 23, 2021 with respect to 3,382 shares of Common Stock and vests in full on the earlier to occur of (a) the first anniversary of the grant date or (b) the date of the next annual meeting of stockholders following the date of grant.
As was previously reported, this option was granted on October 29, 2018 with respect to 38,000 shares of Common Stock, with 33% vesting on October 29, 2019 and the remaining 67% vesting in eight substantially equal quarterly installments thereafter.
The expiration date of the reported grant was mistakenly reported in a Form 4 filed on 10/31/2018 as 10/28/2018.
/s/Jose E. Rivera, Attorney-In-Fact
2021-06-25